# Heat shock protein: potential approach for chemotherapy

By

Md. Rezaul Hoque Sykut

17146055

A thesis submitted to the Department of Pharmacy in partial fulfillment of the requirements for the degree of Bachelor of Pharmacy (Hons.)

Department of Pharmacy
Brac University
November 2021

# Declaration

It is hereby declared that

1. The thesis submitted is my own original work while completing degree at Brac University.
2. The thesis does not contain material previously published or written by a third party, except where this is appropriately cited through full and accurate referencing.
3. The thesis does not contain material which has been accepted, or submitted, for any other degree or diploma at a university or other institution.
4. I have acknowledged all main sources of help.

**Student's Full Name & Signature:**



**Md. Rezaul Hoque Sykut**
17146055

# Approval

The project titled “Heat shock protein: potential approach for chemotherapy” submitted by Md. Rezaul Hoque Sykut (17146055) of Spring, 2017 has been accepted as satisfactory in partial fulfillment of the requirement for the degree of Bachelor of Pharmacy (Hons.) on November 30, 2021.

**Examining Committee:**

Supervisor:



(Member)

Mohammad Kawsar Sharif Siam
Senior Lecturer, Department of Pharmacy,
Brac University

Academic Coordinator:

(Member)

Dr. Zara Sheikh
Assistant Professor, Department of Pharmacy,
Brac University

Departmental Head:

(Chair)

Dr. Eva Rahman Kabir
Professor, Department of Pharmacy,
Brac University

## Ethics Statement

There is no animal or human testing involved in this study.

# Abstract

Overexpression of heat shock proteins occurs in a variety of malignancies in humans. It has also been linked to tumor cell invasion and immune system detection. Several Hsp have also been linked to the prognosis of particular cancers. Hsp70 and Hsp90 expression, for example, Hsp is said to be associated with a worsening prognosis in SCC, breast, bladder, and other cancers. This review article focuses on a collection of medications that have been utilized in cancer clinical trials, as well as the process' approach and outcomes. In addition, the center of attention of this article is the modifying Hsp expression or chaperone activity with pharmaceutical agents, as well as the utilization of Hsps as immunological adjuvants in anticancer vaccines. Furthermore, the applications of software and the future of heat shock protein have been examined.



**Key words:** HSP, treatment options, Hsp90, Docking, Software.

# Dedication

Dedicated to the immense support of my parents, and to my instructors.

# Acknowledgement

First of all, I want to thank Almighty Allah for giving me the strength and the capability to complete the whole project.

In the second place, I'd want to thank and express my sincerest thanks and respect to my most esteemed supervisor, Mohammad Kawsar Sharif Siam, Senior Lecturer, Department of Pharmacy, Brac University, for enabling me to work with him and giving me the chance. Without his consistent assistance, direction, and encouragement, I would not have been able to finish this project. In addition, his devotion and excitement for work, professionalism in teaching, and capability to guide me in the correct direction motivated me to work hard and influenced me to look at challenges in new ways. Moreover, working with him has given me valuable experience that I will use in the future.

After that, I'd want to convey my gratitude and honor to Dr. Eva Rahman Kabir, Professor and Chairperson, Department of Pharmacy, Brac University, as well as all of the Department of Pharmacy's faculty members, for their tremendous assistance and support.

Finally, I'd like to express my gratitude to my parents for their constant encouragement and support in encouraging me to strive harder in all aspect of my life. I feel I would not have made it this far without their prayers, mental support, and unconditional love.

# Table of Contents

**Declaration** ii

**Approval** iii

**Ethics Statement** iv

**Abstract** v

**Dedication** vi

**Acknowledgement** vii

**List of Tables** x

**List of Figures** xi

**List of Acronyms** xii

**Chapter 1: Preface** 1

1.1 Heat shock protein 1

1.2 Cancer cell formation and Hsp 2

1.3 Purpose of Hsp and targeting Hsp 4

1.4 Objective of the research 8

1.5 Methodology 9

**Chapter 2: Overview** 9

2.1 Clinical studies 9

2.2 Combinative therapy 13

**Chapter 3: Experimental drugs and findings** 13

3.1 Apoptozole 14

**3.1.1 Inference** 15

3.2 Luminespib 15

**3.2.1 Inference** 16

3.3 Ganetespib 16

**3.3.1 Inference** 18

3.4 Onalespib 18

**3.4.1 Inference** ..... 19
3.5 Retaspimycin ..... 19
**3.5.1 Inference** ..... 19
3.6 Alvespimycin ..... 20
**Chapter 4: Methodology** ..... **20**
4.1 HSP90 interactivity ..... 21
4.2 Selection of studies using patient sample ..... 24
4.3 HSPs interactivity with extracellular vesicles ..... 25
4.4 HSPs interactivity with plasma membrane ..... 26
4.5 HSPs interactivity with MicroRNAs ..... 27
**Chapter 5: Quantitative methods** ..... **28**
5.1 HSP90 inhibitor molecular docking ..... 29
5.2 Screening & Validating ..... 31
5.3 Analysis based on statistics ..... 34
**Chapter 6: Future perspectives** ..... **35**
**Chapter 7: Concluding Comments** ..... **37**
**References** ..... **38**

# List of Tables

Table 1:  Hsp in cancer development..... 22

Table 2: In silico investigation in breast cancer(Nayarisseri et al., 2013) ..... 32

# List of Figures

Figure 1: HSP90 inhibitors intervention ..... 10

Figure 2: Designing and discovering Hsp90 inhibitor (Li et al., 2009) ..... 11

Figure 3: Ganetespib, an HSP90 inhibitor, and activated JAK/STAT signaling ..... 17

Figure 4: HSP interaction with extracellular vesicles ..... 25

Figure 5: Complete docking process (Albakova et al., 2021) ..... 31

Figure 6: Workflow of the Hsp90 inhibitor development virtual screening protocol (Liu et al., 2019) ..... 33

# List of Acronyms

| | |
|---|---|
| HSP | Heat shock protein |
| HSP90 | Heat shock protein 90 |
| ATP | Adenosine Triphosphate |
| NBD | Neucleotide binding domain |
| SBD | Substrate binding domain |
| BAGS | BAG family protein |
| NEF | Neucleotide exchange factors |
| RMPC | Refractory metastatic pancreatic cancer |
| Cdc37 | Cell division cycle 37 |
| TIN | Telomerase inhibition |
| GIST | Gastrointestinal cancer |
| NSCLC | Non-squamous cell carcinoma |
| SCC | Squamous cell carcinoma |
| STS | Soft-tissue sarcomas |
| kDa | Kilodalton |

| | |
|---|---|
| TRAP1 | Tumor necrosis factor receptor associated protein |
| CRC | Colorectal cancer |
| MMP2 | Metalloproteinase-2 |
| ILK | Integrin Linked Kinase |
| PDA | Pancreatic ductal adenocarcinoma |
| AMPK | Adenosine monophosphate-activated protein kinase |
| MASS | Molecular histidine kinase-pattern profiling |

# Chapter 1: Preface

## 1.1 Heat shock protein

The sort of protein that is produced and upregulated within the cell when the cell is subjected to extreme stress is known as the HSP. Hsp90 is an extremely important chaperone protein that Plays crucial tasks in the appropriate stable the attempt to keep the client proteins present in cancer cells. In the formation of novel structures, researchers have explored the involvement of the thermal shock proteins. They are developed and widely articulated (Albakova et al., 2020). According to the U.S. National Library of Medicine, HSPs have emerged as a one of the most important molecules in the development of cancer and cancer treatment. HSP90 proteins are necessary for the growth of cancer cells. As a result, HSP90 inhibition slows tumor growth while simultaneously increasing the expression of the HSP70 family of proteins. It is necessary for cancer progression for HSP90 for the expression in upper levels.

Proteins that aid inside protein folding and helps restoring misfolded proteins to their normal state are referred to as molecular chaperones (Ozgur & Tutar, 2014) .Furthermore, if the protein is not folded correctly, the functionality of the protein will be greatly impaired, and the cell will die as a result. To avoid this from happening, the cell must ensure that the protein folds correctly. It is because of this that the cell produces unique proteins known as Hsp proteins as a result of the stress factor.



Heat shock protein assists the client protein by preventing degradation and balancing the formation and accumulation of oxygen reactive species in cells (Pizzino et al., 2017). It also protects against hypoxia, a condition where insufficient oxygen reaches the cells and tissues of the body. Even when blood flow is normal, this is conceivable. In regulating or synthesizing the proteins connected to tumorigenic cell development, oncogenes are key. Certain oncoproteins are employed as indicators of tumor. HSPs contain considerable cell proliferation and cell differentiation. In addition, several of their clients have established themselves as oncoproteins in certain tumor types because of their involvement in the molecular orchestration and growth of cancer.

## 1.2 Cancer cell formation and Hsp

A variety of reasons can cause cancer. The proto-oncogenic mutation and when tumor suppressor gene mutates create cancer transformation in the cell. This is because of the fact that the gene modifications make cells normal to cancer cell behavior. For regulating the cell cycle and causing apoptosis, P53 is particularly crucial in point mutation. Since the P53 is inactive, the path of apoptosis is inhibited and cell growth control is avoided. As a consequence, the cell has become cancer cell. KRAS protein ultimately useful for cell cycle development and progression. When RAS remains active and generates a lot of cells, the cell is strongly growing and causing tumor.

After that, cancer can occur in deletion of chromosome-13 in chromosome mutations in the cell cycle regulatory process. As a consequence, cell growth progresses unchecked and cells can become cancer cells. Translocation, where part of the chromosome translocates to another chromosome, causing cancer, is another cause of cancer development (Thompson & Compton, 2011).

HSP90 or heat shock protein helps to ply crucial cancer protein, and Many of the client proteins found in Hsp90, which is involved in apoptosis, also promote cancer growth. This is why it is important for cancer therapeutic targeting. Moreover, several phase I research were chemically investigated with the use of HSP90.

Daunys and his teammates have shown that ICPD47 and ICPD62 inhibitors of HS90 have shown osteosarcoma as well as cervical cancer, and one of the major cancer that is colorectal cancer cell lines were all targets of anti-cancer action. But, in contrast, the activity of these chemicals in

conjunction with the currently utilized anti-cancer medicines It is yet to be examined in the context of tumor cell lines. In the absence of ICPD 47, ICPD 62, and gemcitabine (GEM), and in combination with 5-fluorouracil (5-FU) and the inhibitor of topo-isomerasis, only 5-FU and the inhibitor of topo-isomerasis (doxorubicin) were exposed to pancreatic cells, MTT test determined the effects on cell viability(Daunys et al., 2019). Combinative chemotherapy is commonly employed for cancer treatment. Various pharmaceuticals, when administered in combination, work synergistically, boosting their therapeutic value, reducing dosage, and limiting toxicity compared to using multiple treatments single wisely. The Chou-Talalay method is commonly applied in the calculation of the combination effect by combination index (CI) that establishes a link between a single entity and several entities, as well as first and higher order dynamics. The best technique to assess the combinatorial impact of various drugs is to use combinatorial experiments. The chemicals' synergistic impact (having a CI less than 1 is explained by CI values below 1, while the additive effect (having a CI equal to 1) is described by 1 value, and the antagonistic effect (having a CI greater than 1) is described by another value. (Daunys et al., 2019)

Vorinostat is the inducer of apoptosis by acetylation for HSP90, dissociating HSP90 Her2/ErbB2 and promoting polyubiquitination and Her2/ErbB2 degradation in Her2/ErbB2-overexpressing cancer cells have long lines. Multiple ubiquitin molecules attach to the same target protein. Protein polyubiquitination is the signal that causes the protein to be degraded in the proteasome. As a result, the HSP90 ATP-binding activity is decreased, and the HSP90 androgen receptor is eliminated. In prostate cancer cells, acetylation of HSP90 is promoted with LAQ824. LAQ824 produces effects and apoptosis in prostate cancer cells due to its capability of destroying androgen-induced androgen-specific prostate antigen. LAQ824 decreases other HSP 90 client protein levels as well. (Chen et al., 2005).

| **Compound** | **Function** |
|---|---|
| Vorinostat | Induces apoptosis through HSP90 acetylation |
| Romidepsin | prevents the formation of wildlife or mutant p53 expressing NSCLS cells and promotes apoptosis |

Both of these works by deacetylation efforts. While decreasing the protein quantities of ErbB1, as well as ErbB2, along with Raf-1, and the p53 mutant, Romidepsin only has an effect on the p53 wild type. HSP90 acetylation of p53 and raf-1 is thought to be due to the presence of Romidepsin in the tissue. (Yu, 2002).

## 1.3 Purpose of Hsp and targeting Hsp

HSP help control cellular metabolisms by facilitating protein folding and maintaining protein structures that are critical for cell survival and proliferation. During carcinogenesis, cancer cells seize control of HSPs' defensive functions. Under various intracellular and external stressor situations, HSPs promote proper folding of freshly generated proteins and restore denatured proteins back to their native state. They serve a critical function in ensuring the protein quality. In the progression of cancer, molecular chaperons played a significant role (Yun et al., 2019).

| Molecular chaperons | Role in Cancer Development |
|---|---|
| Hsp27 | HSP27 upregulation promotes the nuclear localization of YAP, a transcription factor of the Hippo pathway that activates oncogenic and metastatic pathways including as TGF-B and SMAD, WNT/B-Catenin, and ILK. |
| Hsp40 | CRC enhances cell cycle progression by decreasing ubiquitin degradation of cell division cycle protein 45 when Hsp40 DNAJ member A1 (DnaJA1) is transcribed with E2F transcription factor 1. (CDC45). |
| Hsp60 | Patients with a poor prognosis exhibited HSP60 expression levels in their HCC tissues that were considerably lower than those in their peritumor tissues. HSP60 inhibition inhibits protein translation and cancer cell proliferation by increasing the production of |

| | |
|---|---|
| | reactive oxygen species (ROS) in the mitochondria. |
| Hsp70 | HSP70 stimulates mitotic signals in cancer cells and protects them from apoptosis and oncogene-induced aging by preventing apoptosis. |
| Hsp90 | When HSP90 is overexpressed, it contributes in carcinogenesis by controlling the folding, stability, and activity of several cancer-promoting proteins. HSP90 physically stabilizes p53-mutant HSP90, preventing DNA damage and growth arrest and apoptosis from occurring in cells. |
| HSF1 | HSF1 regulates Cyclin D, p21, and p27 during mitosis, causing genomic instability and stabilizing mitotic spindle architecture, which aids cancer cell development and progression. |

*Table 1: HSPs in cancer development*(Yun et al., 2019)

In the above table, it shows some of the molecular chaperones and its role in development of cancer. HSP27's multimeric complexes assist stabilize and maintain protein stability by restoring the original shape to denatured or aggregated proteins. It has been found that HSP27 is overexpressed in many different types of malignancies, such as head and neck squamous cell carcinoma and pediatric acute myeloid leukemia. During protein folding and unfolding, as well as HSP70 translocation and degradation, HSP40 plays an important function. Cancers such colorectal, stomach, and lung overexpress several members of the HSP40 family. HSP60 can both promote and repress cancer formation, depending on the condition. Hormonal therapy-induced upregulation of HSP60 promotes tumor growth via regulating mitochondrial homeostasis and activating the mTOR signaling pathway. Blocking HSP60 increases ROS production during retenone-induced AMPK activation in glioblastomas (Yun et al., 2019). An increase in HSP90

synthesis activates oncogenic protein kinases, which supports cancer cell growth. During cellular immortalization, the expression of telomerase reverse transcriptase (hTERT) is usually augmented, and this increased telomerase activity in cancer cells is caused by HSP90 physically interacting with hTERT's promoter (Tang et al., 2016). Studies show that PIM2 phosphorylation increases stabilizes and makes HSF1 more capable of interacting with the PD-L1 promoter by keeping E3 ligase away from HSF1. In vitro and in vivo, increased PD-L1 expression promotes breast cancer growth and carcinogenesis. (Yun et al., 2019).

It is thought that heat shock protein, which has anti-apoptotic properties and is involved in the normal folding of misfolded proteins, is a highly conserved protein. Cells with high levels of HSPs resist death through suppressing caspase-dependent post-mitochondrial apoptosis and other independent mechanisms, which are both found in cancer (Gallucci and Matzinger, 2001). It is possible that each HSP is linked to a variety of compartments. In the cytoplasm and nucleus, HSP70 and HSP90 are detected, while mitochondrial HSP60 and endoplasmic reticulum grp78 are found. Detectable HSPs may also come from microorganisms. The mechanism underpinning HSPs induction has been a major focus of research in the heat-shock response in Escherichia coli.

High levels of Hsps overexpression in malignancies are linked to either a poor prognosis or enhanced resistance to anticancer treatment. Specifically, Hsp90 has emerged as a possible therapeutic target in the fight against cancer. Lysosome–endosome pathways are one possible route for HSP70 release (Mambula and Calderwood, 2006) alternatively a release via secretory-like granules Even so, most research shows that HSP70-oligomers end up in export vesicles' lipid bilayer (Evdonin et al., 2006).

A biomarker's usefulness is dependent on a number of parameters. (Seigneuric et al., 2010). To begin, it's preferable if it's at least. A positive relationship with the condition of interest, as well as overexpression, should be required to discover any further cases. As a result, non-invasive assays that are specific to the disease of interest and easy to quantify are excellent for inducing as early as possible in the disease process to allow for early identification.

The most widely used techniques for the investigation of extracellular HSPs as cancer biomarkers include immunohistochemical (IHC) stainings to detect the presence of a specific HSP in a biopsy, tissue microarrays (TMA), western blot analyses, and enzyme-linked immunosorbent assays

(ELISA), which allow HSP levels to be quantified down to a few nanograms per milliliter but require labels that may denature the protein of interest. (Mjahed et al., 2011).

To find therapeutically useful indicators and therapeutic targets, extracellular vesicles (EVs) can be a useful resource. Particularly interesting is the proteomic analysis of HSPs in EVs derived from various cancer patients' body fluids. As a result, the revelation that patient samples have differing levels of circulating mRNAs (microRNAs) has opened up new diagnostic possibilities for miRNAs. Researchers are also investigating the growing role of miRNAs in HSP regulation in the hunt for blood cancer biomarkers. HSPs are found to be overexpressed in a wide range of cancers. Consequently, they came to the conclusion that HSPs are not effective as tissue specific molecular markers but can be used to evaluate the degree of differentiation and aggressiveness in various malignancies. There have been new possibilities and problems in the hunt for cancer clinical indicators since it was shown that extracellular vesicles are involved in the transmission of proteomic information (mRNAs, microRNAs, and DNA) as well as HSPs in EVs were found.

Some cells, such as those in the human body, secrete phospholipid bilayer-encased particles known as extracellular vacuoles (EVs). Researchers have been able to identify and quantify thousands of EV cargo proteins thanks to improvements in mass spectrometry (MS), allowing them to seek for putative biomarkers in various malignancies. Human telomere length-dependent telomerase (TDP-43) and microRNA (miR-23a) expression in peripheral blood mononuclear cells as potential cancer biomarkers Researchers talk about the expression of various HSP members in EVs derived from various biological fluids and patient samples as cancer biomarkers and a novel perspective on using HSP profiling of EVs released by immune cells as clinical biomarkers and potential targets for investigational therapies (Albakova et al., 2021).

Extremely aggressive cancers usually express HSPs on the surface of their cells. Some HSPs have been found outside of cells, such as on membranes, and are known as extracellular HSPs. An increase in cancer cell proliferation, stage, and poor clinical outcome were found to be associated with extracellular HSP expression, suggesting that HSP expression could be employed in cancer screening. Clinical prospective pilot investigation conducted on lung and breast cancer patients by Gobbo and colleagues indicated that the concentration of HSP70-positive exosomes in plasma was much higher than that seen in healthy volunteers.

Metastatic patients were distinguished from non-metastatic ones using plasma-derived HSP70-positive exosomes rather than tumor cells in the circulation (CTC). According to Campanella and colleagues, HSP60 levels in plasma-derived exosomes were significantly greater in patients with colorectal adenocarcinoma than in healthy controls (Tutar et al., 2014).

Several researchers have used MS proteomic analysis to discover and describe the EV proteome in various cancer tissues and biofluids. EVs isolated from cancer patients' clinical samples have never been studied for their HSP profile before. Examining HSP expression in EVs from various body fluids collected from various MS studies was described to discover a result.

The HSP profile of EVs appears to vary in various cancers and biological fluids. Many HSP families were found in urine-derived EVs, including HSP70 and 90 co-chaperones, indicating that this type of liquid biopsy could be used to identify noninvasive HSP-based biomarkers. Thus, it's discovered by taking blood samples and looking at the hsp value. Analysis of extracellular vesicles from healthy donors to determine their HSP profile.

Natural and synthetic inhibitors of Hsp90 are the two types of inhibitors available. Natural inhibitors come from bacteria or other microrganism, whereas synthetic inhibitors are made in a lab. Radicicol, for example, exhibits no hepatotoxicity as compared to geldanamycin. Some oxime derivatives and cycloproparadicicol, such as KF25706, KF29518, and KF58333, were created to increase the metabolic stability and in vivo activity of radicicol. As synthetic Radicicol has no effect on physical function, it can be said that Hsp can be targeted without affecting bodily function (Albakova et al., 2021).

## 1.4 Objective of the research

The study's goal is to discover effective HSP-based cancer treatments that can be effective in therapy and illustrate the tumors arising from well-understood studies. The research also seeks to identify the cancer treatment. In reality, over-expression of the HSPs offers a selective advantage for malignant cells by targeting or halting planned cell death, and management of immunological reactions. Two major forms of HSPs are formed in stressed cells, characterized by their process of protein folding. Hsp27, Hsp70 and Hsp90 come into touch with the unfolded protein surfaces in the first group. Complex formation circumstances permit the exclusion of folded bulk cytoplasm,

encouraging the emergence of compact active protein conformations. Another aspect is the lack of available medicine and well-known cancer medicine. Seventeen recognized pancreatic cancer chemotherapy medicines are available, but statistics reveal that treatment is not effective today. Resistance to 5-FU and gemcitabine (GEM) increased, according to recent studies. Therefore, new therapeutic drugs are needed, which can serve several goals and improve the effectiveness of pancreas treatment.

## 1.5 Methodology

The study's aim was to synthesize the possible heat shock protein anti-cancer effects. The most popular treatment alternatives are selected and then evaluated based on the findings, so that extremely relevant knowledge of the treatment is discovered. Second, a number of HSP-based therapeutics and a number of HSP-based biomarkers are evaluated by clinical studies (Srivastava & Udono, 1994). For verification of the essential details the source reference to Mendeley and Google Scholar is employed. Finally, statistics, technological research, academic papers, bibliographical literature and unique reports are backed up by the studies' findings. Basic knowledge regarding the mechanisms of useful medicines is collected using Google Search from trusted websites. Finally, a brief debate on the conclusions of the study is held. In order to achieve this objective, a range of sources, such as PubMed, Elsevier, NCBI and Nature, have been used for relevant research publications and articles.

# Chapter 2: Overview

Many studies on HSP were conducted and proposed that cancer could be diagnosed using this as a biomarker because it has crucial cancer functions. The HSP90 molecular chaperone requires ATP to perform its function. This focus on the stressors of the cell reduces the effects of stress. Some oncogenic proteins become essential for tumor cell survival and proliferation. Hsp90 therefore a formidable anti-cancer campaigner. This is followed by an N-terminal nucleotide binding (NBD) segment, which interacts with HSP90 inhibitors and peptide-binding peptides may both be used in combination. The C-terminal region is critical for homodimerization, as is the

middle section, which interacts with client proteins. The C-terminal region of the protein interacts with other proteins and homo-dimersizes proteins. Instead of one domain, HSP70 has two: an NBD and a substrate binding domain (SBD).

## 2.1 Clinical studies

Several experiments employing HSP70 and HSP90 have been conducted and some of the investigations have been carried out yet. These HSP inhibitors can prevent many types of cancer and are examined in clinical trials.




*Figure 1: HSP90 inhibitors intervention*

In the following chart, numerous medicines are investigated to determine the therapeutic effectiveness of cancer prevention of the inhibitor HSP90. For example, in the first and second stages of clinical testing, AT13387 with HSP inhibitor is highly helpful for prostate cancer. The Onalespib medication is then studied and in trial I prevention for advanced solid tumors, primary or triple negative breast cancer, and solid tumors (Albakova et al., 2021). Other medicines that are useful in the clinical trial are also presented in the image above. NSCLC in phase 2 clinical trials, metastatic melanoma in the second phase of the clinical trials and the cancer of advanced breast preferentially in the first and second stages of clinical testing are tested for the drug Retaspimycin.

Luminespib medication intervention by AUY922 is in a clinical investigation and is highly effective for some dangerous malignancy, according to the clinicaltrials.gov and the National library of medicine. In the Ib phase the clinical trial is studied in advanced or metastatic cancer. The medicine is also in the phase I clinical trial of cancer of the blood caused by too many white blood cells or rotten blood cells in the body. Future solid tumor, lymphoma, brain cancer and the ALK +ve NSCLC are also examined by the Luminespib medication. Subsequently, an inhibitor of SNX-5422 Hsp90 is useful for refractive solid tumors, hematological malignancies, neuroendocrine tumors and lung adenocarcinomas. These are all in phase I of the clinical trial. Ganetespib, on the other hand, is one of the main medicines investigated in the clinical trial. The diseases SCLC, acute lymphoblastic leukemia, ocular melanoma, ovarian cancer, and non-skin-controlled NSCLC have been identified. These are selectively conducted in first phase and second phase of the clinical trials. Finally, NVP-BEP800 is investigating A pilot clinical trial was being conducted to research on lymphoblastic cancer.




*Figure 2: Designing and discovering Hsp90 inhibitor (Li et al., 2009)*

This picture demonstrates how the HSP90 inhibitor is designed and the function of HSP90. Hsp90 is available composed of each of which is available as a homodimer of the following domains: an N-term domain that is 25 kDa, an intermediate domain that is 35 kDa, and a domain of C term that is 12 kDa (Pearl et al., 2008). Adenosine triphosphate also seals the "lid" adenosine pocket, and causes the N-terminal to be closed and forms one compact Hsp90 dimer ring-shaped(de Maio et al., 2019). These conformation changes lead to a closing state in which client proteins are no longer active are "clamped." The chaperone cycle drives the ATPase activity of Hsp90. Since most research has been carried out on HSP90 substrates which have a binding domain to the N-terminal parts of ATPs, very few inhibitors that attack the domain discovered for the HSP90 have been identified. Today, these Hsp90 inhibitors are quite exciting because more is still to be found and other inhibitors in this class can produce valuable findings. Other exponents possess a possible veto, although it is not difficult to restrict it. Drug specificity and HSP90 co-dependent inhibitors will receive greater attention in this class since they will have more impact on HSP90 than on the interaction between ATPs. (Vickers et al., 2011).

The client proteins can then be clamped and carried along several oncogenic pathways due to the absence of most Hsp90 ubiquitin targeting proteasome, which may result in additional oncogenic marker in the overall oncogene pathways (Workman, 2004).

Over the course of years, cancer develops, changing its interactions with the immune system in unpredictable ways. HSP70's immunogenicity is due to its ability to bind tumor-derived antigenic peptides. CD8+ T cell response specific for antigen was demonstrated by Blachere and colleagues using the HSP70-peptide complex.

High levels of HSP70 expression are required for cancer cells to survive and grow, as HSP70 depletion activates the oncogene-induced senescence program when present. HSP70 regulates p53 and the cell cycle kinase Cdc2 to prevent aging. Furthermore, HSP70 depletion activates senescence pathways dependent on the expression of various oncogenes, such as p53-dependent or ERK-dependent

Moreover, it is the simultaneous influence on several carcinogenic pathways that is the initial benefits of the Hsp90 targeting which could only be abolished if a specific interaction between the client and Hsp90 is focused on. Validation of the technique targeting Hsp90 would be extremely

difficult, and would need to be done much further. While several studies have compared Hsp90 subtype properties and roles, much of this knowledge remains to be discovered. The different activities of Hsp90 isoforms require additional investigation to examine the isoform selectivity of Hsp90 inhibitors. a very intriguing subject for study, as well as cancer stem cell target marketing is suppression regarding cancer metastases with HS 90 cell-impermeable inhibitors. Given the recognition of importance of CSCs for chemotherapy resistance, by conducting an assessment, a significant amount of data on Hsp90 inhibitors' future influence on CSC characteristics will be revealed.

## 2.2 Combinative therapy

HSPs have emerged as one of the most significant molecules in the research and treatment of cancer, according to the United States National Library of Medicine Cancer cell proliferation necessitates HSP90 proteins. Heat shock proteins (HSPs) are a two-edged sword since they can cause both beneficial and harmful effects. Normal cells use HSP function to maintain protein homeostasis, but cancer cells have adapted to use it for their own survival by coopting it. Consequently, anticancer researchers are very interested in HSPs (Shrestha et al., 2016). There are a number of oncogenic client proteins found in the HSP90 molecular chaperone, all of which contribute significantly to cancer cell hallmarks being initiated. The fact that HSP90 is a cancer therapeutic target is significant. By blocking HSP90, tumor growth is slowed, while the HSP70 gene family is overexpressed. Tumors in humans often have high levels of the HSP70 gene family present. Tumor progression is triggered by high levels of HSP70 expression in cancer cells. When HSP72, HSP72, and HSP72's heat shock cognate 71-kDa proteins, as well as HSC70, are inhibited, this inhibits HSP90 client proteins (Siam et al., 2020).

Breast cancer has a connection between Hsp27, Hsp70, and Hsp90. Overexpression of HSP27 in cancer cells has been linked to resistance to chemotherapeutic drug-induced apoptosis, according to research. Breast cancer cells expressing HSP27 were exposed to doxorubicin inhibition, and the results showed that HSP27 is an anti-apoptotic protein. An further recent study found that upregulating HSP27 in breast cancer cells increased the stability of the HER2 protein and decreased the sensitivity to trastuzumab. It is hoped that HSP27 will prove to be an effective

therapeutic target in the fight against cancer, according to current research (Chatterjee & Burns, 2017). As a powerful anti-apoptotic protein, HSP70 has an impact on both the intrinsic and the extrinsic apoptotic pathways. Mitochondrial membrane permeabilization is prevented by HSP70 because it inhibits stress-induced signal reduction and DNA fragmentation. The p53-p21 pathway, which is involved in aging, is impacted by HSP70. Several studies have connected HSP70 overexpression to treatment resistance (Albakova et al., 2020).

Many oncogenic proteins are stabilized by HSP90 in cancer cells. HSP90 has a number of interactions that may suppress apoptosis. HSP90, for example, has been shown to binding to and inhibiting the oligomerization of apoptotic protease activating factor 1, which prevents the recruitment of procaspase-9 and so preventing the formation of an apoptosome. Furthermore, because of its critical function in telomerase stability, higher production of HSP90 has been linked to senescence resistance. HSP90 is thought to be involved in tumor invasion and metastasis. Intriguingly, Breast cancer bone metastases have been associated to HSP90 inhibitors (Park et al., 2020).

# Chapter 3: Experimental drugs and findings

There are 18 Hsp90 inhibitors in which clinical studies have been conducted. Sadly, there was no Food and Drug Administration approval for Hsp90 inhibitors (FDA). Therefore, more new HSP90 inhibitors need to be further developed and amplified. Some of the most important medications tested and now on the clinical trial are shown in this article.

## 3.1 Apoptozole

It was discovered to be an inhibitor of HSP72 using in silico approaches, It fits its chemical structure to that of a bile salt, and whose chemical composition has a K(a) of -11.0 impulse intramolecular (Zheng et al., 2010). Apoptozole is a high affinity for the HSP72 and it is recently discovered that it binds with high affinity to HSP72 to be viable for therapeutic application. Use

of apoptosis as a tool to assess the results of the double HSP72/HSC70, and its continuing progress included a test able to screen for better pharmacological properties and show the participation of the same property linkages. The scientists ran an FP test to explore at possible interactions among apoptozole and humans, HSP70, which showed a high degree of affinity for this protein and other chemicals with equivalent flexibility. The HSP70 aggregation in apoptozole settings was investigated by surface plasma resonance (SPR), and dynamic light dispersion (DLS) was employed otic check what they were doing during movements. (Evans et al., 2015).

### 3.1.1 Inference

Also known as Apoptozole, this HSP70 inhibitor promotes cancer cell death by causing lysosomal membrane permeabilization. Disruption of lysosomal function by AZ also reduces protective autophagy in many cancer cell types, resulting in cell death. Cervical, colonic, and lung cancers may benefit from it (Yun et al., 2019).

It is because the amino acid residue found in this specific histidine is prevalent in all HSP72 and HSC inhibitors reported to date Apoptozole can have both HSP72 and HSC70 knocked off and the amount of the tumor suppressor was enhanced as a result of it (Siam et al., 2020).

## 3.2 Luminespib

In Luminespib, as a chaperone and regulator of the activity of numerous other proteins, Hsp90 serves as a heat shock protein. HCC is a very aggressive tumor, with a cancerous genetic inter- and intra-tumor heterogeneity, that is challenging to treat due to its malignant properties. Traditional pharmacological therapies yield a modest therapeutic response to molecular targets, and therefore calls for the development of innovative alternatives. HCC treatments (Augello et al., 2019). Apart from preclinical examination on a certain HSP90 inhibitor named AUY922, a DNA mutation that reflects the presence of several HCCs in the beginning, is required prior to determining if it will be a viable drug candidate (luminespib). A number of forms of HSP90 protein are typically expressed, of tumors as remains uncertain about its role in hepatocarcinogenesis.

### 3.2.1 Inference

Higher HCC tissue expression was seen in the normal tissue compared to peritumoral cirrhotic liver tissue. Therapy AUY922 reduced dose-dependent HCC cell proliferation and viability but did so not for ordinary human primary hepatocytes. Dose-dependent treatment AUY922 therapy led to HSP70 being upregulated and HSP90 client protein being simultaneously depleted. Furthermore, treatment promoted either p53-mediated Cleavage of β-catenin and pathway activation, or expression of Mcl-1 based on a cell type or expression, NUPR1. There seems to be a fair probability that HSP90, and AUY922, may be a treatment alternative an effective therapeutic target. (Augello et al., 2019).

## 3.3 Ganetespib

The scarcity of traditional effective pharmacological medicines for the treatment of SCC of the esophagus is currently an ongoing problem. Myc is a client protein susceptible to HSP90, so HSP90 inhibition may be a potential treatment approach to ESCC. This can be an efficient treatment for Ganetespib as for the ESCC cancer(Guan et al., 2020). Additionally, the HSP90 protein (which regulates several other signaling proteins associated with pathogenesis of pancreatic cancer) acts as a tumour suppressor. Ganetespib blocks HSP90 from associating with the inactivation and elimination of cancer by the client's proteins that promoting signaling proteins. Patients who had rMPC received an intravenous infusion of 175 mg/m2 per week of ganetespib on Thursdays for three weeks, followed by four-week cycles of treatments in alternating weeks. (Cardin et al., 2018). After that, Ganetespib has Also susceptible to low toxicity drugs, the hematologic and solid tumor cell lines we studied are very sensitive to drugs in vitro, with drugs having mutant kinases having the highest in vitro cytotoxicity. When subjected to ganetespib treatment, a known Hsp90 client proteins substantial quantity experienced fast degradation, resulting in higher potency than 17-allylamino-17-demethoxygeldanamycin (17-AAG), and degradation occurred even after brief exposure periods. (Ying et al., 2012).




*Figure 3: Ganetespib, an HSP90 inhibitor, and activated JAK/STAT signaling*

Figure 3 shows how JAK signaling can be dysregulated in various ways. JAK2 mutations, particularly, can induce constitutive STAT transcription factor activation, resulting in tumorigenesis. JAK Hsp90 client proteins are commonly known as JAK kinases, as well as Ganetespib, a new small molecule Hsp90 inhibitor, has shown to be effective cultured and malignant cells in vivo that rely on JAK2 activation for survival. JAK2 is depleted after ganetespib treatment, resulting in decreased STAT activity and lower STAT target gene expression (Proia et al., 2011).

### 3.3.1 Inference

STA-9090 or Ganetespib therapy suppressed MYC overexpression resulted in increased the proliferation, advancement of the cell cycle and the survival in ESCC cells. Additionally, STA-9090 reduced expression of MYC, leading the MYC protein to be slowly degraded along ESCC tumors and in the mouse of low-myc animals. It was proved to be effective an in-vivo method, and the results showed that STA-9090 treatment had no beneficial benefits (Guan et al., 2020). For this reason, it can be said that STA-9090 could be a promising new treatment target for MYC-positive ESCC. Ganetespib has potent anticancer action in a variety of JAK/STAT-driven malignancies, and it also has the ability to unruly signaling block by numerous routes. The upstream regulating system JAK2 is successful in Ganetespib. In particular, for degradation in many hematological and solid forms of tumor, the constitutively active JAK2 mutant, resulting to the sustained loss into the STAT3 along with STAT5 signaling (Proia et al., 2011). In RMPC, single agent ganetespib was later found to be tolerated with only little disease control. Given the growing this condition is resistant to chemotherapy since it generates cancer of lung as well as rectal and the pancreatic cancer cell tumors and suggests that ganetespib is more effective in combination with cytotoxic drugs (Cardin et al., 2018).

## 3.4 Onalespib

A pharmacokinetic analysis of onalespib in the brain and plasma, as well the inhibition of HSP90 has been done in animals that not having any tumor as well as in mice without tumors. There is efficacy for TMZ and a single drug in both Zebrafish and GSC xenograft mice models produced from patients. (Canella et al., 2017). Pharmacokinetics along with not having any tumor preliminary efficacy aside with pharmacodynamic effects of HSP70 expression on patient generated PBMCs and plasma are examined for the safety profile and maximum dose toleration, Khanh and colleagues administered the drug using the CDK inhibitor AT7519 in patients with advanced solid cancers that have already advanced (Do et al., 2020).

### 3.4.1 Inference

Onalespib has caused HSP90 suppression by depleting multiple client proteins, interfering with signaling downstream and decreasing glioma and GSC cell growth and migration. In the event that the HSP90 is inhibited and prolongated as a single agent, Onalespib efficiently crossed the BBB(Canella et al., 2017) The onalespib and AT7519 combination is acceptable, but is below RP2D monotherapy. Promising clinical preliminaries were observed. The addition of molecular signature pre-selection can be seen in additional benefits (Do et al., 2020).

## 3.5 Retaspimycin

The pursuit of HSP90 as an anti-cancer approach has increased enthusiasm. In reality, the research has quickly gone from clinical proof of conception investigations as finding that the drug geldanamycin which can inhibit HSP90, several serendipitous findings have emerged indicating GM also inhibits HSP90. It is important that HSP90 is inhibited. gastrointestinal stromal tumor development and progression (GIST). The safety of and maximum tolerant doses of IPI-504, a Novel HSP90 inhibitor, powerful and selectively useful inhibitor that has shown to inhibit GIST metastases and unresectable soft-tissue sarcomas, in addition to metastatic and/or unresectable GIST patients, has been explored by Wagner and his collaborators (Wagner et al., 2013).

### 3.5.1 Inference

For advanced GIST or other STS, retaspimycin is usually well tolerated with some signs of anticancer action, which serves as a clinical evidence that the inhibition of HSP90 continues to be a viable approach. (Wagner et al., 2013). In addition, the 'very sensitive client' does not respond to HSP90 therapy in all cancers. It could be probable as resulting complicated tumor-by-tumour molecular network mediated by HSP90 that might interconnect according to the particular genetic history of the tumor (Jhaveri et al., 2014).

## 3.6 Alvespimycin

HSP90 enables telomerase protein to be assembled and the telomerase inhibition (TIN) can be amplified by the HSP90 alvespimycin inhibitor. To determine the long-term growth rate of osteosarcoma cell lines, imetelstat and alvespimycin were applied to cell lines individually or in combination. (Hu et al., 2015). Park and his fellows mentioned that all Hsp90 paralogs were simultaneously inhibited and demonstrated more active anticancer than other Hsp90-inhibitors by purine scaffold derivative DN401. Pan-Hsp90 inhibition increases cytotoxicity and decreased protective systems for cancer cells, suggesting that the development of effective cancer medicines can be a viable approach (Park et al., 2020)

### 3.6.1 Inference

In the study it was determined that in combined treatments with imetelstat and alvespimycin, telomera activity was reduced and telomeres were shorter than either alone and βH2AX and cleaved caspase-3 were higher. In order to increase the present Hsp90 inhibitors' anticancer potency, mitochondrial TRAP1 could be targeted. Discovering that specific Hsp90 paralogs contribute to proteotoxic stress and elevating cytoplaptical calcium in cancer cells was shown to be due to knocking down all Hsp90 family members simultaneously, along with the application of specialized inhibitors that target particular Hsp90 paralogs (Park et al., 2020).

# Chapter 4: Methodology

It is vital to grasp the relationship between distinct HSP networks when looking for cancer patients extracellular vesicle HSP-based biomarkers as HSP families tend to be strongly related. For instance, the HSP70 or HSP90 DNA vaccines have shown that specific T-cell response affects HSP60. Proof from Many research has shown that the buildup of fat in muscle tissue increases, along with pharmacological enhancers like benzyl alcohol and heptanol. It was associated with modifications in vascular permeability, micro domain solution and thermal stress and an increase of several hundred of temperatures and protein flows. (Balogh et al., 2005). According to Demsey and his associates, the accumulation of inhibitors has indicated that when HSP60 grows in the cells, the HSP60 concentrations decrease and the HSP60 concentration increases in the surface. ,

Dempsey and his team take another view of the reorganization of membrane fluidizers that results in increased HSP70 both inside the cell and intracellularly, both are depleted (Dempsey et al., 2010) Moreover, secretory cell system may allow any enzymes in the secretory cell system to leave and can regulate the lysophases of cancer by high amounts of such enzymes in the lysosomes. (Gehrmann et al., 2008).

## 4.1 HSP90 interactivity

Hsp90 requires a co-chaperone-dependent series of co-assembling co-chaperones in order to operate. When complex assembly is finished, co-chaperones link and detach to govern the procedure (Neckers, 2003). Several phases with unique interactions stopping the chaperone cycle between cochaperone/Hsp90 can have similar implications through Hsp90 is directly inhibited (Y. Li et al., 2009). It appears that the ATP-binding block is the most direct and simplest method of manipulating Hsp90, but it can restrict its further applicability by its internal non-selectivity for the Hsp90 population. A perhaps more particular strategy is to create medicines that disrupt Hsp90-cochaperone interaction. This process would not occur in the absence of a co-chaperone crystal structure. In this procedure, Hsp interacts in order to focus and plays its part for blockade of ATP binding.

| **Interaction with HSP90** | **Role to play** |
|---|---|
| Targeting the cdc37 | In maturing a kinase sub-population of clients cdc37 has a specialist and important role |
| Targeting the HSP70 | The Hsp70/Hsp90 complex is complied with in two TPR independent Hop, TPR1 and TPR2A TPR domains by associations of their C-terminal tail (Yi & Regan, 2008) |
| Targeting the hop | The C-term MEEVD Hsp90 peptide, also used at various places within the C-terminal and the medium fields of the Hsp90 serial is the |

| | |
|---|---|
| | principal binding site for Hop (Onuoha et al., 2008) |
| Targeting the Aha1 | Aha1's interacts with the center segment of Hsp90, The domain interact named as N-term following that interaction causes Hsp90 to go through an ATPase cycle. (Meyer et al., 2004) |

*Table 2: Targeting point of Hsp90 inhibitor*

The target point for HSP90 inhibitors is shown in the table above. As an adapter, Cdc37 loads some of the kinases into the Hsp90 complex and thereby facilitates their ripening. Cdc37 decreases In relation to the connections between kinase clients, such as Her-2 aside with Raf-1 and Cdk4 with Akt, which resulted in a reduced proliferation rate, connections among kinase clients, such as Her-2, Raf-1, Cdk4, and Akt, that resulted in a reduced proliferation rate, have reduced Cdc3 7 in human colon cancer cells. A further notable result that Cdc37 silence did not trigger up-regulation of Hsp70 indicates that Cdc37 may be favorable to target this treatment compares favorably to several HSP90 inhibitors that cause Hsp70 accumulation. A recent study has shown, further and longer depletion and possible cell death might be obtained by inhibiting Hsp90 while using CDc37 silencing an increased number of adverse effects (Smith et al., 2009). Consequently, a possible alternate method has been developed to direct Hsp90 suppression. Inhibition of the interaction of Cdc37/Hsp90 would likely represent a more focused approach and an increased side-effect profile (Gray et al., 2008). Elastrol was also detected to block the connection between Cdec37 and Hsp90 by molecular modeling, using the Cdc37-Hsp90 N-terminal field crystal structure that already exists (Zhang et al., 2018).

After the recent design of CTPR390+, a TPR module that binds to the Hsp90 C-terminal, has proven to be able to compete with endogenous Hsp90. This aims to keep the HSP70/Hsp90 complex from forming, which would activate Her-2 degradation and hence stop breast cancer cell maturation. (Cortajarena et al., 2008).

Surface-detected cancers frequently have higher levels of HSPs (Zheng et al., 2010) Extracellular HSPs are present outside of the cell membranes and in extracellular compartments (Park et al., 2020) Studies have revealed that cell proliferation, progression, and survival are all linked to the extracellular production of HSPs, and suggest that these proteins can be exploited to identify and treat the disease. Extracellular HSPs are covered in this study's findings on the general concept of extracellular HSPs as biomarkers (Cheeseman et al., 2016)

Research found that HSP70-positive nuclear concentration in patients' plasma was significantly higher in a clinical pilot study than in healthy voluntary plasma. (Fujita et al., 2016) In addition, a high-performance Alpha Screen test has been created to uncover new, small chemicals that impede the interactions of Hsp90/TPR2A and the compounds identified to breast cancer cells' proliferation is inhibited, resulting in a decrease in the number of breast cancer cells Her-2. Further, breast cancer is a heterogeneous clinically separated group of disorders that have hormone-positive receptor. The HER2 extracellular domain is linked by trastuzumab. Another HER2 domain binds Pertuzumab, which prevents dimerisation. HSP90 is inhibited by Tanespinycin, which causes HER2 changes in conformation. In addition, Lapatinib is a small-molecular tyrosine kinase inhibitor that targets HER1 and HER2. Likewise, HER1, HER2, and HER4 is inhibited by neratinib (Yi & Regan, 2008). Similar to Cdc37, a decrease in the status of activation of Hsp90 clients was reported recently as well as a synergistic interaction was identified between reduction of Aha1 and administration of 17-AAG. In addition, to restrict cell development, suggesting that regulation of Aha1 could be another treatment approach for use in a clinical trial. (Holmes et al., 2008). Following the client interaction is made possible by a fundamental capacity to comprehend molecular structures and biology.. Hsp90/Cdc37/Cdk4 was purified by use of an electron microscopy and its three-dimensional frame (Pearl et al., 2008). Based on its close association with the Hsp90 ATP pocket, as well as its effects on several Hsp90 clients, it appears as though it has a separate mode of action.

## 4.2 Selection of studies using patient sample

Plasma generated exosomes, according to Campanella and co fellow, mentioned that there are significantly higher from HSP60 levels than in healthy people in patients with colorectal adenocarcinosis. More study of the exosomes of plasma showed that in advanced melanoma patients, HSP70 expression was higher. Many research investigations have shown that blood HSPs can be used to increase the accuracy of cancer diagnosis in the early stages (Hamelin et al., 2011). Although it appears to interact with the ATP pocket of the Hsp90, the fact that it seems to have different modes of action across Hsp90 patients shows that it may be varied. The plasma and serum of several patients were collected to determine the result. In NSCLC, serum antibodies to HSP90 did not show any significant difference between cancer patients and healthy controls. In addition, hsp90 antibodies show little change in serum (Albakova et al., 2021). Serum HSP90AB1 levels is in upper level with SCLC (independent of leukemia grade and stage) and to be more frequent in those with aggressive types of the illness. Finally, the HSP90 antibodies were elevated in patients suffering from illness. SCLC patients had HSP90AB1 in their serum following that, and serum HSP90AB1 was associated with cancer grade and stage. Furthermore, HSP90 antibodies were significantly elevated in patients who were currently experiencing a medical condition compared to healthy individuals. Rong and colleagues have shown that the Hsp90-beta serum test sensitivity and specificity are estimated by utilizing a receiver operator characteristic curve, and a cutoff point is set using the point equivalent to 95% susceptibility and eighty five percent specificity. Normal tissues expressed Hsp90-beta, while lung cancer tissues expressed more of it (P 0.05), and lung cancer patients' serum Hsp90-beta levels were similarly significantly higher than control groups (P 0.05) (Rong et al., 2014). In addition, high level of serum HSP90 levels in melanoma cancer, as opposed to healthy persons. Serum HSP90 levels were found to be completely unrelated to survival, response to chemotherapy, or tumor responsiveness. While these results demonstrate the importance of HSP90 in the HCC cancer cell, they also show that patients with HCC have considerably higher amounts of HSP90 than healthy persons. Moreover, serum HSP90AA1 expression were highly greater into the colorectal cancer patient that of fit participants. That example, HSP90AA1 is significantly significant in colorectal cancer serum (Albakova et al., 2021). The level of membrane fluidization of isolated membrane at these levels by the chemical

agents was equivalent to the increase in membrane fluid found during a thermal change (Balogh et al., 2005)

## 4.3 HSPs interactivity with extracellular vesicles

Scientists cannot yet realize why Hsp90 inhibitors are more sensitive than normal cells to the cell toxicity of cancer cells. Furthermore, why only certain cells with cancer are susceptible to Hsp90. Studies over the last few years have gone through 17-N-allylamino-17-demethoxygelamycin inhibits Hsp90 in both wild mutant type along with cancerous cells, the cancerous cells are significantly more sensitive to inhibitors, for example as the type of 17-N-allylamino-17-demethoxygelamycin. (W. Li et al., 2013). It is vital to identify interactions between various HSP networks in the search for HSP-based biomarkers on the EVs of cancer patients, because families of HSP seem closely connected. For example, HSP70 or HSP90 coded DNA vaccines have shown that they alter a specific HSP60-T cell answer (W. Li et al., 2013). Inhibitors of HSP90 have shown that HSP27 and HSP70 are upgraded to expression.




*Figure 4: HSP interaction with extracellular vesicles*

A proteotoxic stress response mediated by heat shock proteins-1 (HSP1) The cells, such as thermal shocks, oxidative stress, exposure to excessive metals, or proteasome inactivation, will be activated when more nonnative protein conformation is present. HSF1 is found in the nucleus, and HSF1 trimers interact with HSEs, which are present in the promoter area of stress-inducible genes. This process rapidly induces mRNA production. HSP elevations enhance the refolding of proteins to the native functional state in a non-native configuration. The proteostasis level increases, therefore a negative feedback loop is set up. As proteostasis is recovered, HSF1 activity is inhibited, and HSP72 stops it even further. Consequently, the basis for the discovery of numerous biomarkers may be understanding of relations between HSP families as well as knowing interrelations between chaperones and co-chaperone in EVs networks (Lang et al., 2019).

## 4.4 HSPs interactivity with plasma membrane

Recent research demonstrates that changes to the plasma membrane can vary the Hsps level. Furthermore, stress hormones often alter the structure and function of the plasma membrane and so lead to a cascade of events that can impact HSR. The main heat shock factor-1 transactivator combines the uses of plasma membrane signals to control and coordinate numerous heat shock gene expressions. In the past decade, many studies have shown that cells may recognize and react by activating membrane-related signal transduction pathways to stress signals. Given its significant dependence on heat regulated lipid-phase behaviour, the integrity of the membrane nanoplates is believed to result in the redistribution of potential stress sensor/signaling proteins within these subdominations as well as modified activity even if the mild temperature changes. Here we give additional data based on single molecule tracking that even a temperature stress of fever type causes in significant structural alterations to the plasma membrane. In demanding environments like high temperatures, when cells are positioned and other types of physical and chemical stress, they release molecules that impair their ability to function, they become damaged and can no longer carry out their usual functions, or at key stages of organismal development, expression of the latter genes increases. The development of tolerance to future, similar shocks is linked to the overexpression of these genes. Heat shock transcription factor appears to mediate upregulation in response to environmental stressors. In addition to HSP90, various investigations

shows that benzyl alcohol and heptanol have been found to cause membrane fluidity alterations and the remodeling of the microdomain due to heat stress. It leading to the activation of the thermal shock genes which follow soon after. Heat stress in leukemia cells may trigger leukemia has significantly led to the hyper-fluidation of the membrane and membrane rearrangements. In the field of intracellular location and rise of HSP60 and HSP70, Dempsey and his coworkers have found that membrane fluidizers affect HSPs (Albakova et al., 2021; Dempsey et al., 2010).

## 4.5 HSPs interactivity with MicroRNAs

It is also possible that non-coding microRNAs are abundant biomarkers that circulate in the blood. Additionally, binding of the complementary primary miRNA to the mRNA (target messenger RNA, or TgRNA) is responsible for the breaking of long transcripts of mRNA and translation accordingly (Drees & Pegtel, 2020). Aberrant miRNA expression and continuous immunological reactions in the lymphoma tissues can cause circulatory changes of miRNA. Because of its involvement in intercellular communication and organ crosstalk, because extracellular vesicles (EVs) contain miRNAs, EVs are of special importance patients with ESCC and healthy individuals had quantitative, real-time polymerase chain reactions to look for miR-27a (qRT-PCR). In the application using Western blotting has researched the expression of Hsp90 and other essential radioresistance-related proteins.

To explore efficacy of microRNA 27a on the proliferation along with cell death aside cell progress, and radiosensitivity in the cell lines of ESCC along CCK-8 aside the flow of cymetry and analysis of clone survival were utilized. The miR-27a in ESCC patients was decrease in the patients rather in fittest participants., which was downregulated in the plasma. A decreased Hsp90 mRNA and protein occurred when miR-27a was overexpressed in ESCC lines. We have also shown that miR-27 overexpression has led to the degradation of critical radiosistence-related proteins from Hsp90. In associated functional tests, miR-27a dramatically impaired growth, increased apoptosis caused by radiation, G0/G1 cell cycle arrest in-vitro as well as in-vivo improved ESCC radiosensitivity. (Wang et al., 2019). Additionally, diagnosis in the miRNAs, some studies have also employed miRNAs as cancer biomarkers. For instance, high levels of tumor and serum expression among

the members of miR-183 families were related to poor lung cancer outcomes. Promisingly, miRNAs can also be utilized to forecast cancer patients' response to therapy (Albakova et al., 2021)

In addition to the diagnosis of miRNAs, some studies have also employed miRNAs as cancer biomarkers. For instance, high levels of tumor and serum expression among the members of miR-183 families were related to poor lung cancer outcomes. Promisingly, miRNAs can also be utilized to forecast cancer patients' response to therapy. The result indicated a greater expression in lung and sera carcinoma than their normal counterparts of miR-183 family members microRNA 96 expression in malignancies was in line with Sera's expression. The regression analysis of logrank and Cox mentioned, lung cancer patients have a poor overall survival rate due to the miRNA 183 family tumor and serum miRNAs high expression (Zhu et al., 2011).

# Chapter 5: Quantitative methods

In order to discover that the HSP90 inhibitor is a possible biomarker for cancer, various types of experiments have been carried out both outside and employing in silico technology. This is because information is included in the databases and the quantitative structure-activity links can be gathered. The pharmacophores are also helpful to find out. Moreover, this computer technique can also used for other molecular modeling methodologies, such as homology models.

A quick, efficient as well as open design structure prediction must be provided in order to facilitate efficient, reliable and reproducible research on chemicals, the most often used open technique of expansion chemistry package (O'Boyle et al., 2011). To detect the interaction between proteins and proteins, tiny molecular ligands specific to the macromolecular area will be detected. Examples of docking as of the structural drug design process are the expansion or restructuring part of the molecule by locating one or more therapeutic targets in the human biomolecular network. Scientist have created new ways to test a collection of 10 thousands of compounds in the form of multiple compound libraries. Such techniques will be accommodated the simulated screening, in the course of time, of tens of thousands different ligands. Autodock software can reduces the efficiency and accessibility of those who have not been experienced in the computing industry but are used with scientists. In the approach for the development of Alzheimer's malady mechanism the molecular and structural interaction between the selected target was fully and predictably replicated(Goodsell et al., 1996).

The design of a blueprint for certain form combinations, the development of a context around the template and the creation of a CDR followed the 3 processes. The parameters supplied in the run are executed in a row without any additional operator input (Kemmish et al., 2017).

The specialists have helped to strengthen current best practices in our Program in order to employ our protocol efficiently and efficiently. It is useful to employ new computer algorithms to assess outputs but it helps users to occasionally make a more realistic vision of the issue when they are projecting their future performance. Recently, researchers have been more interested in finding new biologics for the type of antibodies because of their success in treating several ailments, including cancer, rheumatism and inflammatory joint diseases. Three-dimensional protein sequences were constructed to create energy, allowing researchers to evaluate qualities as stability (Kemmish et al., 2017).

An additional software called PyMOL enables 3D protein structures to be viewed and non-plate sequences to be searched and non-plateprotein sequences removed from the proteins. It is able to alter, trace and produce chemical materials. PyMOL and several other apps were created to support Python's use and drug production. All Python plugins were produced to offer the use of Python as basic language and Python plugins (Yuan et al., 2017).

The adMET models were based on the techniques that have worked on and further improved this extended issue, named admetSAR 2.0, rather than attempt to design an altogether new methodology. There are 47 alternative models for drug discovery and environmental risk management(Yang et al., 2019)

## 5.1 HSP90 inhibitor molecular docking

Present research studies comprise studies that identified HSP90 more effective inhibitors as the result of protein protein-docking following the achievement of multichaperone HSP90 complex. Modeling of homology is a computer method used with mathematical methods in biological systems for non-covalent bonding, different methodologies and MD simulations. It is striving to target all settings and binding affinities.

Promoting efficient, reliable, and reproducible cheminformatics research is important because the design structure prediction structure must be rapid, efficient, and open. Expansion can be done

with a number of different open methods: Docking is by far the most often utilized. The choice of ligand is another element necessary for the quantitative technique. Ueda and his partner have tested In a living cell context, the HSP90 inhibitor can be detected using this cell-based test approach. Ligand binding activity is tested in this technique by the competition between Hsp90 and the ligand-directed N-acyl-N-alkyl sulfonamide chemical reactions to inhibit labeling of ligand-directed N-acyl-N-alkyl sulfonamide (Ueda et al., 2020). Having extensively employed MODELLER, structure preparation and validation for complete sequence length HSP90, Nayarisseri and his co-op tested. A superior HSP90 inhibition was then studied by using hydrophobic patch identifications, protein-protein-docking and protein-ligand-docking(Nayarisseri et al., 2013).

The molecular docking technique is extensively used for assessing virtual libraries for drug-like molecules, to derive novel compounds for the identification of drugs and needs improvements in the response to future challenge. Mechanistic docking allows scientists to predict the form of experimental holo structures, while holo structures in experimental form are inaccessible.

There are two formats: rigid docking and flexible docking for two different molecular docking types. The flexible portions are not locked in while the torsion is created. Expansion nonetheless has a little more cohesion than expansion, which is extremely binding The molecule is thus superior than the "freely attached" protein as it is docked, and is hence more "expansive" than fixed. To study the kinetics of 2 proteins in this analysis(Albakova et al., 2021). The structure was accepted, and user proteins can be docked, after the proteins were subjected to the structural validation method. In order to improve the amount of positive charging of the protéin structures, polar hydrogen have been introduced.




*Figure 5: Complete docking process* (Albakova et al., 2021)

## 5.2 Screening & Validating

The results include the creation, via relationships Hsp90 and the co-chaperones such as Aha1 and Hsp40, of a multi-chaperon complex, which was generated by a Hsp90 doctrine to its Hsp70 chaperone partner. (an Hsp90:Hsp70 complex) with a negative energy of 711 kcal/mol. Along with Hsp70 and its partners, the following proteins may exist: Chaperones, other chaperones, and Hsp70. Hsp90 forms persistent multi-chaperon complexes that promote robust interactions with p53 mutant relative to wild p53 (Nayarisseri et al., 2013).

| Type of mutant | Docking energy |
|---|---|
| Mutant p53 | −1103.9 kcal/mol |
| Wild type mutant p53 | −894.6 kcal/mol |

*Table 1: In silico investigation in breast cancer*(Nayarisseri et al., 2013)

Table 2 mentioned that the EGCG was shown to be the powerful inhibitor in the 14 hydrogen-bonded Hsp90-containing compounds were formed. docking protein-ligand According to protein attaching with ligand the docking and the similarity in variety of molecule drug binding, 17-DMAG may be used for breast cancer as a medicinal chemical.

Additional research, Sepehri and his collaborators can provide protection against rotavirus infection. pyrimidine The HSP90 molecular and comparative molecular field analyzes were investigated by simulations using interactions with and derived from the N-terminal domain binding site (Sepehri & Ghavami, 2018), and that three new contour maps for this CoMFA model have been taken as a basis for three new inhibitory activities The molecule m45 was connected to the HSP90 domain N binding site, together with tailored inhibitors. Inhibitors were designed to obtain decreased m45 binding energy. A hydroxy group on the phenyl ring is required in order to forge hydrogen-connection in a binding location with hydrophylic residues in a water moleculus by means of a study of the chemical compound m45 in which HSP90 was used as an N-terminal area connection. Molecule m45 has the interaction of pi-sigma with phenyl ring through isopropyl substituent on the side chain Phenylalanine 138 at the phenyl ring meta location. The Van der Waals reaction is another response (Sepehri & Ghavami, 2018)

For understanding biology, as well as for creating new biocatalysts and biotech, it is vital to forecast electrostatic energies. This is why frequent modifications of net electrical charges are needed for virtual screening (due to small molecules and ligand), protein-docking and other testing types such as these; furthermore, protonation status is important and recognizable when preparing therapies for protein interaction.

Energy-friendly intermolecular interaction, like hydrophobic and hydrogen binding in particular, is modest compared to intermolecular interaction, but both crucial within an open conformative protein structure. There have been little evidence that binding factors in the interactions of these drug targets boost efficacy, though they are also valuable to reduce and enhance target specificities. If you wish to have a thorough grip of this subject, it is crucial to learn the hydrophobic link (Patil et al., 2010).

Liu and his team discussed a virtual screening strategy in which novel Hsp90 inhibitors are identified. In the Discovery Studio, a virtual library with 300,000 small compounds was checked and the new Hsp90 inhibitors for biochemical and cellular tests were discovered as 1,3-dibenzyl-2-aryl imidazolidines.




*Figure 6: Workflow of the Hsp90 inhibitor development virtual screening protocol* (Liu et al., 2019)

Figure 5 split the 21 compounds into five groups by distinct characteristics of Liu and his coworkers. MCF-7 cells were assessed with the MTT test for the antiproliferative activity of these

21 substances. IC50 ranged between 21.58 μM and 322 μM. Derivatives are each connected to an scaffold of imidazoline, which have a reasonably powerful cancer control function and a new chemical structure, garnered interest. The highest anti-proliferating activity in imidazolidines was in the cells. Neither anti-cancer medicines, nor Hsp90 inhibitors have been reported for 2-aryl-imidazolidines. Thus, 2-aryl imidazolidine was employed as the principal scaffold to create a second round of Hsp90 inhibitors for development. To find the docking location, the N-terminal region of the ATP binding pocket Hsp90 was examined.

The N-terminal interaction is limited to Hsp90 and cavity was occupied by imidazolidine. The thiophen ring nitrogroup made two hydrogen links, respectively, with PHE124 and ASN37. Hydrophobic bonding with Hsp90 amino acid residues was established within benzyl groups. This study suggested that a two-position imidazolidine hydrogen binding accepter and a hydrophobic fragment in nitrogen atoms were conducive to Hsp90, which is a type of molecule (Liu et al., 2019). These new Hsp90 inhibitors have demonstrated obvious anti-proliferative effect against cell lines MCF-7 and A549. These chemicals showed significant affinity with human Hsp90α in the test for characteristics of Hsp90 molecular biomarkers, Her2 and Hsp70 and Hsp90 uplift the expression in MCF-7 (Liu et al., 2019).

## 5.3 Analysis based on statistics

On average, 39 percent of CRC patients had elevated levels of Hsp40 compared to individuals in stages I–III. An additional type II hetero-oligomeric chaperonin (TRiC/CCT) in the HSP60 family helps fold around 10% of cytosolic proteins that cannot be folded by existing chaperone systems. This chaperone complex, which includes HSP60, HSP70, and HSP90, is thought to impact HBV synthesis and secretion in the liver HepG2.2.15 cell line, according to comparative proteomic study. Furthermore, antisense oligonucleotide therapy directed against HSP60 has a significant impact on HBV replication (Park et al., 2020). The immunohistochemistry (IHC) study made use of 223 different gastric cancer samples. HSP60 immunohistochemistry in gastric cancer tissues was used to elucidate the biological importance of HSP60 in this disease. Tumor cell cytoplasm mostly stained with HSP60. HSP60 was found to be present in gastric cancer samples at a rate of 58.3 percent (130/223) (X. Li et al., 2014). Hsp72 is most likely to alter the sensitivity of cancer

cells to hyperthermia, which is employed in clinics together with radiation and chemotherapeutic treatments like chemotherapy. About half of the cells in the DU-145/siHsp72 and PC-3/siHsp72 strains died after being exposed to 45°C for 20 minutes, although heat shock in the ancestral cells had minimal effect on apoptosis (Gabai et al., 2005). The total 3-year survival rate was 63.75 percent in the HSP90-negative expression group. HSP90-positive expression had a 3-year survival rate of 45.46 percent, in contrast. P=0.0172 showed a significantly worse prognosis for the patients in the HSP90-positive expression group (n=20) than for the patients in the HSP90-negative expression group. HSP90 may serve as a prognostic indicator in HCC, according to these findings. HSP90 expression is also a predictor of three-year overall survival in HCC patients (LIU et al., 2016).

NSCLC patients with tumors containing an ALK rearrangement showed the most promising single-agent activity, with a lasting response observed in 50% of patients. Ganetespib and crizotinib results that patients with ALK-rearranged metastatic NSCLC who had not previously taken crizotinib were also recently studied in a phase I research. (67% response rate)

# Chapter 6: Future perspectives

Hsp90, a molecular chaperone, requires ATP for stabilization and activation of about 200 client proteins. diverse and distinctive properties of many oncogenic signaling proteins are determined by their own stability and functionality of cancer is necessary. Genetic instability enables the eight markings outlined by Hanahan and Weinberg to develop for one cancer cell(Hanahan & Weinberg, 2000). These are autonomous development signals, insensitivity to indications against growth, avoiding the apoptosis.

Cancers caused by infectious viruses may be prevented by prophylactic vaccines that protect against viral infection. For the prevention of malignancies linked to the human papillomavirus (HPV) and hepatitis B virus (HBV), the FDA has approved two types of preventive cancer vaccinations (Igarashi & Sasada, 2020). utilizing anticancer vaccines, for example. It's been discovered that HSP-based anticancer vaccines are effective against a wide range of cancers that express antigens, as they not only encourage APCs to take up antigens but also activate T

lymphocytes. Although it is still a difficulty, increasing the effectiveness of activated CTLs penetrating the tumor microenvironment(Das et al., 2019)

Developing more efficient immunotherapeutic techniques may be made easier with a greater understanding of how HSPs modulate the tumor microenvironment. Combination therapies have increased the safety and efficacy of anticancer vaccines, including the use of chaperone-based immunotherapy in conjunction with immune-checkpoint inhibitors like CTLA-4, PD-1, and PD-L1 inhibitors, in particular. Chemotherapy and radiotherapy can be made more effective by sensitizing cancer cells to HSP-targeted therapy.

After that, angiogenesis maintained, invasion of tissue and metastases along with unlimited potential replicative. Finally, the energy metabolism reprogramming and immune destruction avoidance. Cancer cells are able to evade molecularly targeted therapies because of genetic plasticity, which permits them to escape each signaling node or pathway that they're addressed to (Chiosis & Neckers, 2006). As recently as in Synta Pharmaceuticals, a Hsp90 inhibitor drug conjugate (HDC) platform technology was described. By enhancing the efficiency of the cytotoxic chemotherapeutic agents, HDCs reduce collateral harm to normal cells. Cancer treatment medication complexes that contain a Hsp90 inhibitor (targeting moiety) attached to an anti-cancer substance (payload) are administered by intravenous injection, and the linker which is designed to release the payload inside cancer cells is cleaved to help control the release of the payload. the contribution to tumor Hsp90 attracting moieties by activating Hsp90 in tumors, which draws HDC molecules to tumors. Higher concentration and longer duration of the active payload medicine occur when regular administration of unconjugated chemotherapy or other payloads is done however the concentrations and durations are higher when unconjugated chemotherapy or other payloads are given. the improved delivery can help cancer cells to be more effectively eliminated, as well as decreasing negative effects (Tatokoro et al.,2015)

Next-generation medications are possible with these 40+ HDCs, which include chemotherapeutics, kinase inhibitors, hormone treatments, immunomodulators, and epigenetic modifiers. The use of this revolutionary strategy may lead to reduced side effects of present chemotherapy and a wide range of malignancies may be resistant to standard treatments. (Rong et al., 2014).

# Chapter 7: Concluding Comments

The study mentions multiple attempts to shed light on several main HSPs, their utility as diagnostic biomarkers, their regulatory functions in driving various signaling cascades, and lastly, how targeting HSPs has emerged as an unique and potential cancer therapy method. Highly potent and selective HSP90 inhibitors have aided in the understanding of the role of this molecular chaperone family in biology and disease pathology. However, significant progress has been made in the production of useful chemical tool molecules, which could pave the way for future clinical therapeutic possibilities. Understanding the mechanisms of action of various HSPs and addressing these concerns would greatly aid in the development of innovative anticancer drugs that target HSPs precisely and effectively. Aside from small molecule inhibitors, significant preclinical and clinical success has been achieved in identifying other approaches to target HSPs with higher selectivity and anticancer efficacy. By incorporating active agents into a suitable delivery mechanism, the nanocarriers, nanomedicine presents us with a new age drug delivery platform. Over the last two decades, cancer immunotherapy has advanced dramatically. T cells that detect tumor-specific antigens that are abundantly expressed in cancer tissues have been found. Despite the fact that it is clear that certain HSPs play key roles as tumor suppressors and that their overexpression could aid the development of targeted cancer therapies, medicines to selectively activate these HSPs have proven to be difficult to develop to date. In conclusion, this is still a developing field with great potential for the future.

# References


Albakova, Z., Armeev, G. A., Kanevskiy, L. M., Kovalenko, E. I., & Sapozhnikov, A. M. (2020). HSP70 Multi-Functionality in Cancer. *Cells*, *9*(3). https://doi.org/10.3390/cells9030587

Albakova, Z., Siam, M. K. S., Sacitharan, P. K., Ziganshin, R. H., Ryazantsev, D. Y., & Sapozhnikov, A. M. (2021). Extracellular heat shock proteins and cancer: New perspectives. *Translational Oncology*, *14*(2). https://doi.org/10.1016/j.tranon.2020.100995

Augello, G., Emma, M. R., Cusimano, A., Azzolina, A., Mongiovì, S., Puleio, R., Cassata, G., Gulino, A., Belmonte, B., Gramignoli, R., Strom, S. C., McCubrey, J. A., Montalto, G., & Cervello, M. (2019). Targeting HSP90 with the small molecule inhibitor AUY922 (luminespib) as a treatment strategy against hepatocellular carcinoma. *International Journal of Cancer*, *144*(10). https://doi.org/10.1002/ijc.31963

Balogh, G., Horváth, I., Nagy, E., Hoyk, Z., Benkõ, S., Bensaude, O., & Vígh, L. (2005). The hyperfluidization of mammalian cell membranes acts as a signal to initiate the heat shock protein response. *The FEBS Journal*, *272*(23), 6077–6086. https://doi.org/https://doi.org/10.1111/j.1742-4658.2005.04999.x

Canella, A., Welker, A. M., Yoo, J. Y., Xu, J., Abas, F. S., Kesanakurti, D., Nagarajan, P., Beattie, C. E., Sulman, E. P., Liu, J., Gumin, J., Lang, F. F., Gurcan, M. N., Kaur, B., Sampath, D., & Puduvalli, V. K. (2017). Efficacy of Onalespib, a Long-Acting Second-Generation HSP90 Inhibitor, as a Single Agent and in Combination with Temozolomide against Malignant Gliomas. *Clinical Cancer Research*, *23*(20). https://doi.org/10.1158/1078-0432.CCR-16-3151

Cardin, D. B., Thota, R., Goff, L. W., Berlin, J. D., Jones, C. M., Ayers, G. D., Whisenant, J. G., & Chan, E. (2018). A Phase II Study of Ganetespib as Second-line or Third-line Therapy for Metastatic Pancreatic Cancer. *American Journal of Clinical Oncology*, *41*(8). https://doi.org/10.1097/COC.0000000000000377

Chatterjee, S., & Burns, T. (2017). Targeting Heat Shock Proteins in Cancer: A Promising Therapeutic Approach. *International Journal of Molecular Sciences*, *18*(9). https://doi.org/10.3390/ijms18091978

Cheeseman, M. D., Westwood, I. M., Barbeau, O., Rowlands, M., Dobson, S., Jones, A. M., Jeganathan, F., Burke, R., Kadi, N., Workman, P., Collins, I., van Montfort, R. L. M., & Jones, K. (2016). Exploiting Protein Conformational Change to Optimize Adenosine-Derived Inhibitors of HSP70. *Journal of Medicinal Chemistry*, *59*(10). https://doi.org/10.1021/acs.jmedchem.5b02001

Chen, L., Meng, S., Wang, H., Bali, P., Bai, W., Li, B., Atadja, P., Bhalla, K. N., & Wu, J. (2005). Chemical ablation of androgen receptor in prostate cancer cells by the histone deacetylase inhibitor LAQ824. *Molecular Cancer Therapeutics*, *4*(9). https://doi.org/10.1158/1535-7163.MCT-04-0287

Chiosis, G., & Neckers, L. (2006). Tumor Selectivity of Hsp90 Inhibitors: The Explanation Remains Elusive. *ACS Chemical Biology*, *1*(5). https://doi.org/10.1021/cb600224w

Cortajarena, A. L., Yi, F., & Regan, L. (2008). Designed TPR Modules as Novel Anticancer Agents. *ACS Chemical Biology*, *3*(3). https://doi.org/10.1021/cb700260z

Das, J. K., Xiong, X., Ren, X., Yang, J.-M., & Song, J. (2019). Heat Shock Proteins in Cancer Immunotherapy. *Journal of Oncology*, *2019*. https://doi.org/10.1155/2019/3267207

Daunys, S., Matulis, D., & Petrikaitė, V. (2019). Synergistic activity of Hsp90 inhibitors and anticancer agents in pancreatic cancer cell cultures. *Scientific Reports*, *9*(1). https://doi.org/10.1038/s41598- 019-52652-1

de Maio, A., Cauvi, D. M., Capone, R., Bello, I., Egberts, W. V., Arispe, N., & Boelens, W. (2019). The small heat shock proteins, HSPB1 and HSPB5, interact differently with lipid membranes. *Cell Stress and Chaperones*, *24*(5). https://doi.org/10.1007/s12192-019-01021-y

Dempsey, N. C., Ireland, H. E., Smith, C. M., Hoyle, C. F., & Williams, J. H. H. (2010). Heat Shock Protein translocation induced by membrane fluidization increases tumor-cell sensitivity to chemotherapeutic drugs. *Cancer Letters*, *296*(2), 257–267. https://doi.org/10.1016/j.canlet.2010.04.016

Do, K. T., O'Sullivan Coyne, G., Hays, J. L., Supko, J. G., Liu, S. v., Beebe, K., Neckers, L., Trepel, J. B., Lee, M.-J., Smyth, T., Gannon, C., Hedglin, J., Muzikansky, A., Campos, S., Lyons, J., Ivy, P., Doroshow, J. H., Chen, A. P., & Shapiro, G. I. (2020). Phase 1 study of the HSP90 inhibitor onalespib in combination with AT7519, a pan-CDK inhibitor, in patients with advanced solid tumors. *Cancer Chemotherapy and Pharmacology*, *86*(6). https://doi.org/10.1007/s00280-020-04176-z

Drees, E. E. E., & Pegtel, D. M. (2020). Circulating miRNAs as Biomarkers in Aggressive B Cell Lymphomas. *Trends in Cancer*, *6*(11). https://doi.org/10.1016/j.trecan.2020.06.003

Evans, L. E., Cheeseman, M. D., Yahya, N., & Jones, K. (2015). Investigating Apoptozole as a Chemical Probe for HSP70 Inhibition. *PLOS ONE*, *10*(10), e0140006-. https://doi.org/10.1371/journal.pone.0140006

Fujita, Y., Yoshioka, Y., & Ochiya, T. (2016). Extracellular vesicle transfer of cancer pathogenic components. *Cancer Science*, *107*(4). https://doi.org/10.1111/cas.12896

Gabai, V. L., Budagova, K. R., & Sherman, M. Y. (2005). Increased expression of the major heat shock protein Hsp72 in human prostate carcinoma cells is dispensable for their viability but confers resistance to a variety of anticancer agents. *Oncogene*, *24*(20). https://doi.org/10.1038/sj.onc.1208495

Gehrmann, M., Liebisch, G., Schmitz, G., Anderson, R., Steinem, C., de Maio, A., Pockley, G., & Multhoff, G. (2008). Tumor-specific Hsp70 plasma membrane localization is enabled by the glycosphingolipid Gb3. *PLoS ONE*, *3*(4). https://doi.org/10.1371/journal.pone.0001925

Goodsell, D. S., Morris, G. M., & Olson, A. J. (1996). Automated docking of flexible ligands: Applications of autodock. *Journal of Molecular Recognition*, *9*(1). https://doi.org/10.1002/(SICI)1099-1352(199601)9:1<1::AID-JMR241>3.0.CO;2-6

Gray, P. J., Prince, T., Cheng, J., Stevenson, M. A., & Calderwood, S. K. (2008). Targeting the oncogene and kinome chaperone CDC37. *Nature Reviews Cancer*, *8*(7). https://doi.org/10.1038/nrc2420

Guan, L., Zou, Q., Liu, Q., Lin, Y., & Chen, S. (2020). HSP90 Inhibitor Ganetespib (STA-9090) Inhibits Tumor Growth in c-Myc-Dependent Esophageal Squamous Cell Carcinoma . *OncoTargets and Therapy*, *Volume 13*. https://doi.org/10.2147/OTT.S245813

Hamelin, C., Cornut, E., Poirier, F., Pons, S., Beaulieu, C., Charrier, J.-P., Haïdous, H., Cotte, E., Lambert, C., Piard, F., Ataman-Önal, Y., & Choquet-Kastylevsky, G. (2011). Identification and verification of heat

shock protein 60 as a potential serum marker for colorectal cancer. *The FEBS Journal*, *278*(24), 4845–4859. https://doi.org/https://doi.org/10.1111/j.1742-4658.2011.08385.x

Hanahan, D., & Weinberg, R. A. (2000). The Hallmarks of Cancer. *Cell*, *100*(1). https://doi.org/10.1016/S0092-8674(00)81683-9

Holmes, J. L., Sharp, S. Y., Hobbs, S., & Workman, P. (2008). Silencing of HSP90 Cochaperone AHA1 Expression Decreases Client Protein Activation and Increases Cellular Sensitivity to the HSP90 Inhibitor 17-Allylamino-17-Demethoxygeldanamycin. *Cancer Research*, *68*(4). https://doi.org/10.1158/0008-5472.CAN-07-3268

Hu, Y., Bobb, D., He, J., Hill, D. A., & Dome, J. S. (2015). The HSP90 inhibitor alvespimycin enhances the potency of telomerase inhibition by imetelstat in human osteosarcoma. *Cancer Biology & Therapy*, *16*(6). https://doi.org/10.1080/15384047.2015.1040964

Igarashi, Y., & Sasada, T. (2020). Cancer Vaccines: Toward the Next Breakthrough in Cancer Immunotherapy. *Journal of Immunology Research*, *2020*. https://doi.org/10.1155/2020/5825401

Jhaveri, K., Ochiana, S. O., Dunphy, M. P., Gerecitano, J. F., Corben, A. D., Peter, R. I., Janjigian, Y. Y., Gomes-DaGama, E. M., Koren, J., Modi, S., & Chiosis, G. (2014). Heat shock protein 90 inhibitors in the treatment of cancer: current status and future directions. *Expert Opinion on Investigational Drugs*, *23*(5). https://doi.org/10.1517/13543784.2014.902442

Kemmish, H., Fasnacht, M., & Yan, L. (2017). Fully automated antibody structure prediction using BIOVIA tools: Validation study. *PLOS ONE*, *12*(5). https://doi.org/10.1371/journal.pone.0177923

Lang, Guerrero-Giménez, Prince, Ackerman, Bonorino, & Calderwood. (2019). Heat Shock Proteins Are Essential Components in Transformation and Tumor Progression: Cancer Cell Intrinsic Pathways and Beyond. *International Journal of Molecular Sciences*, *20*(18). https://doi.org/10.3390/ijms20184507

Li, W., Tsen, F., Sahu, D., Bhatia, A., Chen, M., Multhoff, G., & Woodley, D. T. (2013). *Extracellular Hsp90 (eHsp90) as the Actual Target in Clinical Trials*. https://doi.org/10.1016/B978-0-12-407697-6.00005-2

Li, X., Xu, Q., Fu, X., & Luo, W. (2014). Heat Shock Protein 60 Overexpression Is Associated with the Progression and Prognosis in Gastric Cancer. *PLoS ONE*, *9*(9). https://doi.org/10.1371/journal.pone.0107507

Li, Y., Zhang, T., Schwartz, S. J., & Sun, D. (2009). New developments in Hsp90 inhibitors as anti-cancer therapeutics: Mechanisms, clinical perspective and more potential. *Drug Resistance Updates*, *12*(1–2). https://doi.org/10.1016/j.drup.2008.12.002

LIU, X., CHEN, S., TU, J., CAI, W., & XU, Q. (2016). HSP90 inhibits apoptosis and promotes growth by regulating HIF-1α abundance in hepatocellular carcinoma. *International Journal of Molecular Medicine*, *37*(3). https://doi.org/10.3892/ijmm.2016.2482

Liu, Y., Liu, X., Li, L., Dai, R., Shi, M., Xue, H., Liu, Y., & Wang, H. (2019). Identification and Structure-Activity Studies of 1,3-Dibenzyl-2-aryl imidazolidines as Novel Hsp90 Inhibitors. *Molecules*, *24*(11). https://doi.org/10.3390/molecules24112105

Meyer, P., Prodromou, C., Liao, C., Hu, B., Mark Roe, S., Vaughan, C. K., Vlasic, I., Panaretou, B., Piper, P. W., & Pearl, L. H. (2004). Structural basis for recruitment of the ATPase activator Aha1 to the Hsp90 chaperone machinery. *The EMBO Journal*, *23*(3). https://doi.org/10.1038/sj.emboj.7600060

Nayarisseri, A., Moghni, S. M., Yadav, M., Kharate, J., Sharma, P., Chandok, K. H., & Shah, K. P. (2013). In silico investigations on HSP90 and its inhibition for the therapeutic prevention of breast cancer. *Journal of Pharmacy Research*, *7*(2). https://doi.org/10.1016/j.jopr.2013.02.020

Neckers, L. (2003). Development of Small Molecule Hsp90 Inhibitors: Utilizing Both Forward and Reverse Chemical Genomics for Drug Identification. *Current Medicinal Chemistry*, *10*(9). https://doi.org/10.2174/0929867033457818

O'Boyle, N. M., Banck, M., James, C. A., Morley, C., Vandermeersch, T., & Hutchison, G. R. (2011). Open Babel: An open chemical toolbox. *Journal of Cheminformatics*, *3*(1). https://doi.org/10.1186/1758-2946-3-33

Onuoha, S. C., Coulstock, E. T., Grossmann, J. G., & Jackson, S. E. (2008). Structural Studies on the Co-chaperone Hop and Its Complexes with Hsp90. *Journal of Molecular Biology*, *379*(4). https://doi.org/10.1016/j.jmb.2008.02.013

Ozgur, A., & Tutar, Y. (2014). Heat Shock Protein 90 Inhibitors in Oncology. *Current Proteomics*, *11*(1). https://doi.org/10.2174/15701646111666140415224635

Park, H.-K., Yoon, N. G., Lee, J.-E., Hu, S., Yoon, S., Kim, S. Y., Hong, J.-H., Nam, D., Chae, Y. C., Park, J. B., & Kang, B. H. (2020). Unleashing the full potential of Hsp90 inhibitors as cancer therapeutics through simultaneous inactivation of Hsp90, Grp94, and TRAP1. *Experimental & Molecular Medicine*, *52*(1). https://doi.org/10.1038/s12276-019-0360-x

Patil, R., Das, S., Stanley, A., Yadav, L., Sudhakar, A., & Varma, A. K. (2010). Optimized Hydrophobic Interactions and Hydrogen Bonding at the Target-Ligand Interface Leads the Pathways of Drug-Designing. *PLoS ONE*, *5*(8). https://doi.org/10.1371/journal.pone.0012029

Pearl, L. H., Prodromou, C., & Workman, P. (2008). The Hsp90 molecular chaperone: an open and shut case for treatment. *Biochemical Journal*, *410*(3). https://doi.org/10.1042/BJ20071640

Pizzino, G., Irrera, N., Cucinotta, M., Pallio, G., Mannino, F., Arcoraci, V., Squadrito, F., Altavilla, D., & Bitto, A. (2017). Oxidative Stress: Harms and Benefits for Human Health. *Oxidative Medicine and Cellular Longevity*, *2017*. https://doi.org/10.1155/2017/8416763

Proia, D. A., Foley, K. P., Korbut, T., Sang, J., Smith, D., Bates, R. C., Liu, Y., Rosenberg, A. F., Zhou, D., Koya, K., Barsoum, J., & Blackman, R. K. (2011). Multifaceted Intervention by the Hsp90 Inhibitor Ganetespib (STA-9090) in Cancer Cells with Activated JAK/STAT Signaling. *PLoS ONE*, *6*(4). https://doi.org/10.1371/journal.pone.0018552

Rong, B., Zhao, C., Liu, H., Ming, Z., Cai, X., Gao, W., & Shuanying, Y. (2014). Identification and verification of Hsp90-beta as a potential serum biomarker for lung cancer. *American Journal of Cancer Research*, *4*, 874–885.

Sepehri, B., & Ghavami, R. (2018). Towards the In-silico Design of New HSP90 Inhibitors: Molecular Docking and 3D-QSAR CoMFA Studies of Tetrahydropyrido [4, 3-d] Pyrimidine Derivatives as HSP90 Inhibitors. *Medicinal Chemistry*, *14*(5). https://doi.org/10.2174/1573406414666180321151029

Shrestha, L., Bolaender, A., J. Patel, H., & Taldone, T. (2016). Heat Shock Protein (HSP) Drug Discovery and Development: Targeting Heat Shock Proteins in Disease. *Current Topics in Medicinal Chemistry*, *16*(25). https://doi.org/10.2174/1568026616666160413141911

Siam, M. K. S., Karim, A., & Shohan, M. U. S. (2020). In-Silico Study for Potential Inhibitors of Both HSP72 and HSC70 Proteins in the Treatment of Cancer. *ACM International Conference Proceeding Series*, 61–67. https://doi.org/10.1145/3429210.3429226

Smith, J. R., Clarke, P. A., de Billy, E., & Workman, P. (2009). Silencing the cochaperone CDC37 destabilizes kinase clients and sensitizes cancer cells to HSP90 inhibitors. *Oncogene*, *28*(2). https://doi.org/10.1038/onc.2008.380

Srivastava, P. K., & Udono, H. (1994). Heat shock protein-peptide complexes in cancer immunotherapy. *Current Opinion in Immunology*, *6*(5), 728–732. https://doi.org/10.1016/0952-7915(94)90076-0

Tang, H., Li, J., Liu, X., Wang, G., Luo, M., & Deng, H. (2016). Down-regulation of HSP60 Suppresses the Proliferation of Glioblastoma Cells via the ROS/AMPK/mTOR Pathway. *Scientific Reports*, *6*(1). https://doi.org/10.1038/srep28388

Thompson, S. L., & Compton, D. A. (2011). Chromosomes and cancer cells. *Chromosome Research*, *19*(3). https://doi.org/10.1007/s10577-010-9179-y

Ueda, T., Tamura, T., & Hamachi, I. (2020). Development of a Cell-Based Ligand-Screening System for Identifying Hsp90 Inhibitors. *Biochemistry*, *59*(2). https://doi.org/10.1021/acs.biochem.9b00781

Vickers, K. C., Palmisano, B. T., Shoucri, B. M., Shamburek, R. D., & Remaley, A. T. (2011). MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. *Nature Cell Biology*, *13*(4). https://doi.org/10.1038/ncb2210

Wagner, A. J., Chugh, R., Rosen, L. S., Morgan, J. A., George, S., Gordon, M., Dunbar, J., Normant, E., Grayzel, D., & Demetri, G. D. (2013). A Phase I Study of the HSP90 Inhibitor Retaspimycin Hydrochloride (IPI-504) in Patients with Gastrointestinal Stromal Tumors or Soft-Tissue Sarcomas. *Clinical Cancer Research*, *19*(21). https://doi.org/10.1158/1078-0432.CCR-13-0953

Wang, X., An, D., Liu, X., Wang, X., & Li, B. (2019). MicroRNA-27a downregulates the expression of Hsp90 and enhances the radiosensitivity in esophageal squamous cell carcinoma . *OncoTargets and Therapy*, *Volume 12*. https://doi.org/10.2147/OTT.S197456

Workman, P. (2004). Combinatorial attack on multistep oncogenesis by inhibiting the Hsp90 molecular chaperone. *Cancer Letters*, *206*(2). https://doi.org/10.1016/j.canlet.2003.08.032

Yang, H., Lou, C., Sun, L., Li, J., Cai, Y., Wang, Z., Li, W., Liu, G., & Tang, Y. (2019). admetSAR 2.0: web-service for prediction and optimization of chemical ADMET properties. *Bioinformatics*, *35*(6). https://doi.org/10.1093/bioinformatics/bty707

Yi, F., & Regan, L. (2008). A Novel Class of Small Molecule Inhibitors of Hsp90. *ACS Chemical Biology*, *3*(10). https://doi.org/10.1021/cb800162x

Ying, W., Du, Z., Sun, L., Foley, K. P., Proia, D. A., Blackman, R. K., Zhou, D., Inoue, T., Tatsuta, N., Sang, J., Ye, S., Acquaviva, J., Ogawa, L. S., Wada, Y., Barsoum, J., & Koya, K. (2012). Ganetespib, a Unique Triazolone-Containing Hsp90 Inhibitor, Exhibits Potent Antitumor Activity and a Superior Safety

Profile for Cancer Therapy. *Molecular Cancer Therapeutics*, *11*(2). https://doi.org/10.1158/1535-7163.MCT-11-0755

Yu, X. (2002). Modulation of p53, ErbB1, ErbB2, and Raf-1 Expression in Lung Cancer Cells by Depsipeptide FR901228. *CancerSpectrum Knowledge Environment*, *94*(7). https://doi.org/10.1093/jnci/94.7.504

Yuan, S., Chan, H., & Hu, Z. (2017). Using PyMOL as a platform for computational drug design. *Wiley Interdisciplinary Reviews: Computational Molecular Science*, *7*, e1298. https://doi.org/10.1002/wcms.1298

Yun, C. W., Kim, H. J., Lim, J. H., & Lee, S. H. (2019). Heat Shock Proteins: Agents of Cancer Development and Therapeutic Targets in Anti-Cancer Therapy. *Cells*, *9*(1). https://doi.org/10.3390/cells9010060

Zhang, C., Leng, W., Sun, C., Lu, T., Chen, Z., Men, X., Wang, Y., Wang, G., Zhen, B., & Qin, J. (2018). Urine Proteome Profiling Predicts Lung Cancer from Control Cases and Other Tumors. *EBioMedicine*, *30*. https://doi.org/10.1016/j.ebiom.2018.03.009

Zheng, H., Nagaraja, G. M., Kaur, P., Asea, E. E., & Asea, A. (2010). Chaperokine Function of Recombinant Hsp72 Produced in Insect Cells Using a Baculovirus Expression System Is Retained. *Journal of Biological Chemistry*, *285*(1). https://doi.org/10.1074/jbc.M109.024612

Zhu, W., Liu, X., He, J., Chen, D., Hunag, Y., & Zhang, Y. K. (2011). Overexpression of members of the microRNA-183 family is a risk factor for lung cancer: A case control study. *BMC Cancer*, *11*(1). https://doi.org/10.1186/1471-2407-11-393